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     INTRODUCTION 
  Malaria remains an important public health challenge in 
southern Laos with a median incidence of   Plasmodium fal-
ciparum   infection of 4.7–23.5/1,000 population.  1   As in many 
other tropical countries, antimalarial drug resistance to   P. fal-
ciparum   poses a public health threat. The Lao Government 
changed national policy for first-line antimalarial drug treat-
ment of uncomplicated   P. falciparum   malaria to artemether-
lumefantrine (AL) in 2005. This artemisinin-combination 
treatment (ACT) and artesunate-mefloquine both have high 
efficacies and good tolerability with 42-day failure rates of 
≤ 6% in Laos.  2,  3   However, there is uncertainty as to the clini-
cal importance of reduced bioavailability of lumefantrine 
when taken without fatty food,  4–  8   especially with evidence of 
resistance to artemisinin derivatives in adjacent Cambodia 
increasing the required contribution to efficacy by the partner 
drug.  9,  10   Artemether-lumefantrine has to be taken twice a day, 
which reduces adherence. 
  Dihydroartemisinin-piperaquine (DP) is a potential 
alternative; it can be taken once a day, does not have food-
dependent bioavailability, and can be produced for a lower 
cost than AL. A trial comparing DP (Artekin  ™ ;  Holleykin 
Pharmaceutical Co., Guangzhou, China) with artesunate 
(Guilin Pharmaceutical Co., Guilin, China) plus mefloquine 
(Lariam  ™  ; Roche, Basel, Switzerland) in southern Laos dem-
onstrated that DP had a 100% cure rate (n = 110) assessed at 
42 days-follow up.  11   The DP used in this study was produced 
in compliance with Chinese Good Manufacturing Practice 
(GMP) standards, but not with the GMP standards required 
by drug regulatory authorities in Europe or the United States. 
A DP formulation produced to standards compliant with 
International Conference on Harmonization GMP has been 
developed by Sigma-Tau (Rome, Italy) with support from the 
Medicines for Malaria Venture (MMV). 
  We therefore conducted a phase III, randomized, non-
inferiority trial of this new formulation to assess the efficacy 
and safety in comparison with artesunate-mefloquine (AM) 
in patients with acute, uncomplicated   P. falciparum   malaria in 
Laos. This study was part of a multi-center study in Asia that 
included India, Laos, and Thailand.  12   This paper reports the 
detailed results from Laos and their implications. 
   MATERIALS AND  METHODS 
    Study site, patients, clinical procedures, and laboratory 
investigation.     The study was conducted during June–October 
in 2005 and 2006 at Phalanxay (10 beds) and Xepon (30 beds) 
District Clinics and during June–October 2006 at Xepon 
District Clinic, Savannakhet Province. Phalanxay and Xepon 
districts (Savannakhet Province) are located 605 km and 665 
km, respectively, southeast of Vientiane, the capital of Laos. 
Phalanxay (78 villages, population = 24,730) and Xepon (88 
villages, population = 48,000) are inhabited predominantly by 
rice farmers of the Lao Theung ethnic group.  2,  11,  13,  14   A  sample 
size calculation was performed for the whole multi-center 
study. For Laos, 300 patients were assigned to be recruited.  12  
 Patient inclusion and exclusion criteria have been reported.  12  
At presentation, venous blood samples were obtained for 
parasite count, hematologic tests, and biochemical tests; three 
blood spots were collected on 3MM filter paper (Whatman, 
Maidstone, United Kingdom) for genotyping by polymerase 
chain reaction (PCR) in the event of reappearance of   P. falci-
parum  during follow-up.  13  A 12-lead electrocardiogram (ECG) 
(CarTouch; Cardionics S.A., Belgium) was obtained. 
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  If the study inclusion criteria were met, the patients were 
randomly assigned to receive either 1) AM: artesunate (Artesu-
nate, 100 oblong Lactab; Mepha, Aesch-Basel, Switzerland), 
4 mg/kg/day for 3 days (days 0–2) plus mefloquine (Mephaquin 
Lactab; Mepha, Aesch-Basel), 15 mg base/kg on day 1 and 
10 mg base/kg on day 2 or 2) DP: dihydroartemisinin-piper-
aquine (Sigma-Tau), 2.1/16.8 mg/kg in a single daily dose for 
3 days. Each tablet contained 40 mg of dihydroartemisinin and 
320 mg of piperaquine for adults and 20 mg of dihydroartemisi-
nin and 160 mg of piperaquine for children < 15 years of age. 
The use of AM and DP in this study was reviewed and approved 
by the Food and Drug Department, Ministry of Health, Laos. 
  The treatment choice was kept in a sealed opaque envelope, 
which was opened only after the decision to recruit had been 
made. An unequal randomization, 2:1 (DP:AM), was used to 
provide more precise estimates of DP cure rates and to provide 
more patients for the safety database of DP. Axillary tempera-
ture was measured every six hours. Study drug administration 
was observed directly by the study physicians. Study medica-
tions administered to older children (> 5 years of age) and 
adults were given as tablets or fractions of tablets orally with 
a glass of water and those given to young children (≤ 5 years 
of age) were crushed, mixed with water, and administered as 
a slurry if the children were unable to swallow. Patients were 
observed for one hour to ensure that the medications were not 
vomited or regurgitated.  12  
  Patients were reviewed daily until parasite clearance was 
observed, then weekly for 63 days from the start of treatment, 
or at other times if he or she was ill. At each visit, finger prick 
blood was obtained for a malaria blood smear and hemat-
ocrit. Three blood spots were collected on filter paper from 
those with reappearance of asexual parasitemia for genotyp-
ing.  15   Twelve-lead ECGs were obtained on days 2 and 7 and 
on days 28 and 63 if the ECG result was abnormal on day 7; 
ECGs were also obtained on the day of   P. falciparum   recur-
rence. Venous blood samples were obtained for hematologic 
and biochemical tests on days 28 and 63 if the results were 
abnormal on day 28 and were also performed on the day of 
  P. falciparum   recurrence. 
  Patients who received AM and had recurrent   P. falciparum  
parasitemia or treatment failure were withdrawn from the 
study, re-treated with oral artesunate (2 mg/kg/day) plus 
doxycycline (4 mg/kg/day) (or artesunate alone for children 
< 8 years of age) for 7 days and followed-up. Those persons 
who received DP and had recurrent   P. falciparum   para-
sitemia or treatment failure were withdrawn from the study, 
re-treated with AM for three days, and followed-up. Patients 
in whom severe disease developed  16   or required rescue ther-
apy were re-treated with intravenous artesunate, 2.4 mg/kg/
day initially, and then oral or intravenous drug to give a total 
treatment course of 12 mg/kg over 7 days. Those persons who 
received additional courses of therapy were also followed-
up for 63 days. Potential adverse events were recorded for 
those ≥ 3 years of age and able to answer questions about 
these symptoms. Written informed consent was obtained 
from all adult participants and from parents or legal guard-
ians of minors. Ethical clearance for the study was obtained 
from the Lao National Ethics Committee for Health Research 
and the Oxford University Tropical Medicine Research Ethics 
Committee, United Kingdom. The trial registration number is 
ISRCTN81306618. The trial was monitored by MDS Pharma 
Services  ( http://www.mdsps.com/ ). 
  Parasite counts in thick and thin blood films stained with 
Field’s stain were obtained daily until parasite clearance and 
then weekly from day 7.  13   Polymerase chain reaction amplifi-
cation was performed on paired samples for parasite genotyp-
ing to distinguish between reinfection and recrudescence.  15  
   Outcome  measures.     The primary end point was the PCR-
corrected adequate clinical and parasitologic response PCR-
ACPR at day 63 by using World Health Organization (2003) 
guidelines.  17   Analysis was performed for each patient until 
either day 63 or until the reappearance of   P. falciparum  
parasites. 
  Secondary end points were 1) crude or PCR-uncorrected 
adequate clinical and parasitologic response, 2) proportion of 
patients with treatment failure at or after day 7, 3) propor-
tion of aparasitemic patients on days 1, 2, and 3, 4) parasite 
clearance time (time in days from first treatment dose to the 
first thick blood film negative for   P. falciparum   parasites after 
checking ≥ 500 oil-immersion microscopic fields), 5) propor-
tion of a febrile patients on days 1, 2, and 3, 6) fever clear-
ance time (time in hours from the start of treatment at which 
the axillary temperature first decreased below 37.5°C and 
remained below 37.5°C for 48 hours), 7) gametocyte carriage 
(blood slide positive for gametocytes) after treatment, 8) frac-
tional changes in hematocrit after antimalarial treatment, and 
9) adverse events. 
   Statistical  analysis.     Data were analyzed by using SPSS 
version 11.0 (SPSS, Chicago, IL). Comparisons between two 
groups were made by using the Mann-Whitney U test, the 
Student’s   t  -test, the chi-square test, and Fisher’s exact tests, 
as appropriate. Cure rates were calculated as the proportion 
of patients with PCR-confirmed recrudescence by using 
intention-to-treat (ITT) and per-protocol (PP) populations.  17  
In the ITT population, all losses to follow-up were treated 
as failures. In the PP population, losses to follow-up were 
excluded from the analysis. Patients with new infections were 
regarded as cures in both analyses. Survival analysis (Kaplan-
Meier estimates) was used to calculate cure rates by using Stata 
version 9 (StataCorp, College Station, TX) for all randomized 
patients.  18   Patients with new infections were censored at the 
time of the new infection, and patients lost to follow-up were 
censored at their last visit. Confidence intervals (CIs) for the 
difference in cure rates calculated for the PP population were 
estimated by using Newcombe’s method and were used to test 
the non-inferiority hypothesis.  19  
  Gametocyte carriage was summarized as person-gametocytes-
week rates calculated as the total number of weeks with game-
tocytes divided by the total number of weeks of follow-up and 
presented as per 1,000 person-weeks. 
    RESULTS 
  The numbers of patients screened for malaria and enrolled 
in the trial is shown in   Figure 1  . The admission features of the 
two study groups were similar (  Table 1  ). At the time of enroll-
ment, 129 (43%) patients were afebrile but had a history of 
fever prior to admission. The proportion of patients without 
documented fever on admission was similar in the AM and 
DP groups. Most patients (68%, 205 of 300) were children 
(≤ 15 years of age) (69 of 98 in AM group and 136 of 202 in 
the DP group). Two patients in the DP group refused to swal-
low the study tablets, and three patients had persistent vom-
iting after taking study drugs, and thus were excluded from 1223 DIHYDROARTEMISININ-PIPERAQUINE FOR P. FALCIPARUM MALARIA
the study and were not followed-up. Therefore, 98 (100%) and 
197 (97.5%) patients in AM and DP groups, respectively, com-
pleted 63 days of follow-up (  Figure 1  ). 
        Cure  rates,  fever  and  parasite  clearance,  and  changes  in 
hematocrit and hemoglobin levels.     Severe disease developed 
in a four-year-old girl who had uncomplicated   P. falciparum  
malaria (97,968 parasites/μL). She had one 5-minute convulsion 
30 hours after receiving AM and remained unconscious 
(Glasgow Coma Score ≥ 9/15) for 70 minutes. She recovered 
after receiving supportive treatment. This patient was not 
excluded from the study and completed 63 days of follow-up 
and showed cure. 
  Of 8 and 12 patients with subsequent   P. falciparum   reap-
pearance in the AM and DP groups, respectively, PCR analysis 
indicated that only one patient, in the DP group, had a recru-
descent infection. If we considered the four-year-old patient 
with the convulsion and coma after treatment as an early 
treatment failure, the 63-day cure rates per protocol, exclud-
ing patients who refused to swallow tablets or had persistent 
vomiting, or experienced re-infection, were 99% (97 of 98) 
for AM and 196 of 197 (99.5%) for DP. The difference (AM 
minus DP) in cure rates (95% CI) of −0.5% (−5.1 to 2.0%) 
is within the 5% non-inferiority margin. After censoring the 
patient who had convulsions, those experiencing re-infec-
tions and those who refused to swallow the study drugs or had 
repeated vomiting, the cure rates (95% CI) by survival analysis 
(Kaplan-Meier) were 100% for AM and 99.5% (96.4–99.8%) 
for DP (  Table 2  ). If the four-year-old girl with severe disease 
was considered an early treatment failure, the cure rates (95% 
CI) were 99.0% (93.0–99.9%) and 99.5% (96.4–99.9%) for 
the AM and DP groups, respectively. Conventional intention-
to-treat analysis showed that the 63-day cure rates adjusted 
for re-infection were 99% (97 of 98) for AM and 97% (196 of 
202) for DP (  P   = 0.43). Similarly, 28-day cure rates by inten-
tion-to-treat analysis were 99% (97 of 99) for AM and 97.5% 
(197 of 202) for DP. Intention-to-treat and per protocol anal-
yses showed that the 63-day PCR-uncorrected cure rates for 
AM and DP were 89 of 98 (91%) versus 190 of 202 (94%) 
(  P  = 0.16), and 89 of 91 (91%) versus 185 of 197 (94%) ( P  = 0.33), 
respectively. The number of patients with   P. vivax   appearance in 
the AM and DP groups during follow-up was similar (  Table 2  ). 
            At presentation, 57% of all patients had fever, as defined 
by a body temperature ≥ 37.5°C. At day 2, 99% and 97.5% 
in AM and DP groups, respectively, were afebrile (  P   = 0.67), 
and all patients (except one in the DP group) had no parasites 
detected. The median fever and parasite clearance times were 
similar between the AM and DP groups ( Table 2 ). Comparison 
of baseline (day 0) and day 28 mean hematocrits showed that 
anemia improved significantly after treatment in the AM and 
DP groups (  P   < 0.001 for both, by paired   t -test)  ( Table  2 ). The 
mean hematocrit on day 7 was significantly higher in the DP 
group than in the AM group (  P   = 002). Mean leukocyte counts 
were significantly higher on day 28 than on day 0 in both treat-
ment groups (  P   < 0.001). 
 Figure 1.        Patient flow diagram. +ve = positive;   Pf   =   Plasmodium falciparum ;   Pv   =   P. vivax ;   Pm   =   P .   malariae  ; AM = artesunate-mefloquine; 
DP = dihydroartemisinin-piperaquine; PCR = polymerase chain reaction.       1224 MAYXAY AND OTHERS
      Comparisons between adults and children.    The  mean 
admission temperature was significantly higher in children 
(38.0°C [37.8–38.1°C]) than adults (37.7°C [37.4–37.9°C]) 
(  P   = 0.04). A palpable spleen (47% and 4%;   P   < 0.001) 
and liver (25% and 2%,   P   < 0.001) were significantly more 
frequent in children than adults. The admission geometric 
mean parasitemia/μL was significantly higher in children than 
adults (13,718 parasites/μL [10,578–17,795 parasites/μL) versus 
6,471 parasites/μL [4,578–9,147 parasites/μL]) (  P   = 0.001), 
as were the proportions of patients with clinical anemia and 
vomiting at presentation (41 [20%] of 205 versus 1 [1%] of 
95;   P   < 0.001 and 94 [46%] of 205 versus 29 [30.5%] of 95; 
  P  = 0.01; respectively). The frequency of the following admission 
symptoms and signs were significantly lower in children than 
 Table 2 
    Outcome measures for the treatment of patients enrolled in a study comparing AM and DP for treatment of   Plasmodium falciparum   malaria in 
Laos *   
Variable
Treatment groups
All (n = 300) AM (n = 98) DP (n = 202)
63-day cure rate, no. (%) of patients  †  – 97/98 (99) 196/202 (97)
63-day cure rate per protocol, no. (%) of patients – 97/98 (99%) 196/197 (99.5)
63-day cure rate by survival analysis, % (95% CI) – 100 99.5 (96.4–99.8)
Fever clearance time, median hours (range)  †    ‡  22 (7–68) 24 (7–68) 21 (7–64)
Parasite clearance time, median days (range)  †    §  2 (1–3) 2 (1–2) 2 (1–3)
Positive parasitemia at day 1, no. (%) of patients 199/298 (67) 70/98 (71) 129/200 (64.5)
Positive parasitemia at day 2, no. (%) of patients 1/298 (0.3) 0 1/200 (0.5%)
Gametocytemia after treatment, no. (%) of patients 7/300 (2.3) 1/98 (1) 6/202 (3)
  P. vivax   appearance after treatment of   P. falciparum  , no. (%) of patients 10/295 (3) 2/98 (6) 4/197 (2)
Day 0 hematocrit, mean % (95% CI) 36.6 (35.8–37.4)  ¶  35.9 (34.6–37.3)   ¶  36.9 (35.9–38.0)   ¶ 
Day 7 hematocrit, mean % (95% CI)  #  32.6 (32.0–33.3) 31.6 (30.5–32.7) 33.1 (32.4–34.0)
Day 28 hematocrit, mean % (95% CI) 38.6 (38.2–39.1) 38.2 (37.4–39.0) 38.8 (38.2–39.5)
    *     AM = mefloquine plus artesunate for 3 days; DP = dihydroartemisinin plus piperaquine for 3 days; CI = confidence interval.  
  †   Intention-to-treat  analysis.  
    ‡     Data were available from only 81 and 151 patients in the AM and DP groups, respectively.   
    §     Data were available from only 98 and 197 patients in the AM and DP groups, respectively.   
    ¶     Significant difference from day 28 (  P   < 0.01).   
    #     Significant difference between AM and DP groups (  P   = 0.02).   
 Table 1 
    Admission demographic, clinical, and laboratory details for patients in a study comparing AM and DP for treatment of   Plasmodium falciparum  
malaria  in  Laos *   
Variable
Treatment groups
All (n = 300) AM (n = 98) DP (n = 202)
Sex, Male, no. (%) 179 (60) 59 (60) 120 (59)
Age, years 14.4 (12.8–16.0) 14.1 (11.2–17.0) 14.6 (12.7–16.5)
Body weight, kg 29.3 (27.2–31.4) 28.2 (24.5–31.9) 29.8 (27.2–32.4)
Previous malaria attack, no. (%) of patients  †  99 (33) 34 (35) 65 (32)
Axillary temperature, °C 37.9 (37.7–38.0) 37.9 (37.7–38.2) 37.9 (37.7–38.0)
Patients without fever on admission, no. (%) 129 (43) 39 (40) 90 (44.5)
Systolic blood pressure, mm Hg  ‡  103.3 (101.8–104.9) 104.5 (101.6–107.4) 102.8 (100.9–104.6)
Diastolic blood pressure, mm Hg  ‡  64.5 (63.3–65.7) 65.0 (62.8–67.3) 64.2 (62.8–65.7)
Pulse, beats/min 109.6 (107.1–112.0) 110.2 (105.6–114.9) 109.2 (106.3–112.2)
Splenomegaly, no. (%) of patients 100 (33) 37 (38) 63 (31)
Hepatomegaly, no. (%) of patients 54 (18) 21 (21) 33 (16)
Parasitemia, geometric mean parasites/μL 20,564 (17,873–23,659) 22,851 (18,433–28,333) 18,505 (15,438–22,182)
Erythrocytes/mm  3  4.91 (4.81–5.02) 4.79 (4.62–4.96) 4.97 (4.85–5.10)
Hemoglobin, g/dL 11.4 (11.1–11.7) 11.2 (10.7–11.7) 11.5 (11.1–11.8)
Hematocrit, % 36.6 (35.8–37.4) 35.9 (34.6–37.3) 36.9 (35.9–38.0)
Leukocytes/mm  3  6,679 (6,322–7,035) 6,754 (6,237–7,270) 6,642 (6,173–7,112)
PMN, % 61.8 (60.4–63.2) 63.6 (61.2–65.9) 60.9 (59.2–62.7)
Lymphocytes, % 34.5 (33.2–35.8) 33.4 (31.2–35.7) 35.1 (33.4–36.7)
Platelets/mm  3  108,010 (100,44–115,536) 109,375 (96,369–122,380) 107,351 (98,050–116,653)
ALT, IU/L, median (range) 24 (6–272) 23 (7–131) 25 (6–272)
AST, IU/L, median (range) 33 (12–361) 32 (14–244) 33 (12–361)
GGT, IU/L, median (range) 15 (6–584) 15 (7–584) 15 (6–238)
Alkaline phosphatase, IU/L 149.6 (141.7–157.4) 152.2 (139.8–164.5) 148.3 (138.2–158.3)
Total bilirubin, μmol/L 16.7 (15.4–17.9) 18.3 (15.6–21.2) 15.9 (14.5–17.1)
Direct bilirubin, μmol/L 4.3 (3.9–4.8) 4.8 (3.9–5.5) 4.1 (3.6–4.6)
Total protein, g/L 68.5 (67.6–69.3) 68.4 (67.0–69.7) 68.5 (67.5–69.5)
Blood urea nitrogen, mmol/L 4.6 (4.3–4.8) 4.8 (4.3–5.2) 4.5 (4.2–4.8)
Creatinine, μmol/L 48.6 (46.0–51.3) 46.8 (42.4–45.2) 48.6 (46.0–52.2)
Glucose, mmol/L 5.9 (5.7–6.1) 6.1 (5.6–6.6) 5.8 (5.6–6.0)
Albumin, g/L 35.5 (35.0–36.0) 36.0 (35.0–37.0) 35.0 (34.0–36.0)
    *      Values are presented as mean (95% confidence intervals) unless otherwise indicated. AM = mefloquine plus artesunate for 3 days; DP = dihydroartemisinin plus piperaquine for 3 days; 
PMN = polymorphonuclear leukocytes; ALT = alanine aminotransferase; AST = aspartate aminotransferase, GGT = γ-glutamyl transferase.   
    †     Defined as patient or patient’s guardian reporting that the patient had had a febrile illness with a positive malaria slide.  
    ‡     Data were available from only 201 patients in DP group   1225 DIHYDROARTEMISININ-PIPERAQUINE FOR P. FALCIPARUM MALARIA
adults: weakness (154 [75%] of 205 versus 85 [89%] of 95; 
  P   = 0.004), muscle pain (32 [15%] of 205 versus 80 [84%] of 
95;   P   < 0.001), headache (144 [70%] of 205 versus 91 [96%] 
of 95;   P   < 0.001), nausea (76 [37%] of 205 versus 48 [50.0%] 
of 95;   P   = 0.02), pruritis (0% versus 3 [3%] of 95;   P   < 0.03), 
and tinnitus (3 [1%] of 205 versus 15 [16%] of 95;   P   < 0.001). 
  The median and range fever and parasite clearance times 
were not significantly different between children (23 [7–64] 
hours and 2 [1–3] days) and adults (21 [7–68] hours and 2 
[1–2] days) (  P   = 0.48 and 0.06, respectively, by Mann-Whitney 
U test). Mean hematocrit values on admission and on all days 
between days 7 and 63 were significantly lower in children 
than in adults (  P   < 0.001) in both treatment groups. 
   Plasmodium falciparum  gametocyte carriage.   Twenty-three 
(7.7%) patients had patent gametocytemias on admission, 
6 (6%) in the AM group and 17 (8%) in the DP group 
(  P   = 0.48). The time to clearance of gametocytes was longer in 
the DP group than in the AM group. All patients in the AM 
group and only 8 (47%) patients in the DP group cleared their 
gametocytemias by day 7 (  P   = 0.048, by Fisher’s exact test). 
After treatment, gametocytemia developed on day 56 in one 
patient in the AM group who did not have gametocytemia on 
admission at the same time as a new   P. falciparum   infection. 
Gametocytemia also developed after admission (days 1–2), 
which cleared by day 14, in 6 other patients in the DP group 
who did not have gametocytemia on admission. The proportion 
of patients in whom gametocytemia developed in the AM and 
DP groups was not significantly different (  P   = 0.68). Person-
gametocyte-weeks was estimated as 12 weeks/1,000 patients 
in the AM group and 22 weeks/1,000 patients in the DP group 
(  P   = 0.069). The proportion of patients with gametocytemia at 
any time point was higher in children (13%, 27 of 205) than 
in adults (3%, 3 of 95) (  P   = 0.006, by Fisher’s exact test), and 
the proportion of patients with gametocytemia after treatment 
was 4% (7 of 185) in children and 0% (0 of 92) in adults 
(  P   = 0.10, by Fisher’s exact test). 
    Adverse  events.     Adverse events were reported by 269 
(89.7%) patients ≥ 3 years of age who were able to answer 
questions about these symptoms. A convulsion and coma 
developed in a four-year-old patient after treatment with 
AM (see above). Severe malaria or other life-threatening 
events after treatment did not develop in any other patients. 
The frequency of patients with symptoms and signs before 
treatment that may subsequently be confused with drug-
related adverse events did not differ significantly between 
groups (  P   > 0.05). The proportion of patients with at least one 
recorded potential side effect/adverse event after treatment 
was significantly higher in the AM group (38 of 87, 44%) than 
in the DP group (57 of 182, 31%) (  P   = 0.04). The incidence of 
post-treatment dizziness, nausea, insomnia, and anorexia were 
all significantly higher in AM group than in the DP group 
(  P   ≤ 0.01) (  Table 3  ). The frequency of some adverse events was 
significantly higher in adults than in children (see above). 
        Electrocardiograms.   No significant ECG abnormalities were 
found before or after treatment. The mean ECG-determined 
heart rate was significantly lower after treatment at days 2 
and 7 for both treatment groups (  P   < 0.001) than at admission 
(  Table 4  ). The mean PR interval was significantly longer after 
treatment (on days 2 and 7) than on admission for both groups 
(  P   ≤ 0.001): mean PR interval (95% CI) difference between 
baseline and days 2 and 7 were −9.5 (−13.1 to −6.0) and −5.7 
(−9.1 to −2.4), respectively, for the AM group and −5.3 (−7.1 
to −3.5) and −3.6 (−5.6 to −1.6), respectively, for the DP group. 
Four patients (two in the AM group and two in the DP group) 
had PR interval prolongation (> 200 ms) after treatment on 
day 2 or day 7 but the PR intervals on day 7 or day 28 were 
normal. The mean QRS interval was also significantly longer 
on day 2 than on admission (  P   = 0.001) but was similar to the 
baseline value by day 7 (  P   > 0.05) in both treatment groups 
( Table  4 ). 
      Modeling  the  QT/RR  relationship 20–  22   gave a correction 
formula of QR/RR0.521 pre-drug, QR/RR0.478 on day 2, and 
QR/RR0.493 on day 7. Because this calculation approximates 
to Bazzet’s formula (QTc = QT/RR × 0.5), Bazzet’s correc-
tion was used. There was weak negative correlation or no 
correlation between QTc and RR intervals at baseline or 
after treatment (  Table 4  ). The mean (95% CI) QTc (ms) was 
 Table 3 
    Possible adverse events in patients in a study comparing AM and DP 
for treatment of   Plasmodium falciparum   malaria  in  Laos *   
Sign or symptom
Prior to treatment 
(n = 300)
After treatment
AM 
(n = 98)
DP 
(n = 202)   P 
At least one AE  †  95 (35) 38 (44) 57 (31) 0.04
Cardiologic AE  ‡  61 (20) 16 (16) 45 (22) 0.23
T-wave abnormality 1 (0.3) 0 1 (0.5) 1.00
Complete bundle block  §  2 (0.7) 2 (2) 0 0.10
Prolonged QTc  ¶  38 (13) 12 (12) 26 (13) 0.88
Sinus bradycardia 5 (1.7) 1 (1) 4 (2) 1.00
Sinus tachycardia 15 (5) 3 (3) 12 (6) 0.40
Sinus arrhythmia 6 (2) 1 (1) 5 (2.5) 0.67
ST change 1 (0.3) 0 1 (0.5) 1.00
Extrasystole 1 (0.3) 1 (1) 0 0
Vertigo  †  16 (6) 12 (14) 4 (2) < 0.001
Cough 4 (1.3) 3 (3) 1 (0.5) 0.10
Nausea  †  11 (4) 10 (11) 1 (0.5) < 0.001
Vomiting 10 (3.3) 5 (5) 5 (2.5) 0.30
Insomnia  †  4 (1.5) 4 (4.5) 0 0.01
Fever 3 (1) 0 3 (1.5) 0.55
Lung abnormality  #  24 (8) 7 (7) 17 (8) 0.70
Influenza 23 (8) 6 (6) 17 (8) 0.48
Weakness 3 (1) 2 (2) 1 (0.5) 0.25
Headache  †  14 (5) 8 (9) 6 (3) 0.07
Tinnitus  †  2 (0.7) 0 2 (1) 1.00
Labial herpes 1 (0.3) 1 (1) 0 0.32
Lymph node 1 (0.3) 1 (98) 0 0.32
Sore throat  †  1 (0.4) 1 (1) 0 0.32
Convulsion 1 (0.3) 1 (1) 0 0.32
Diarrhea 4 (1.3) 2 (2) 2 (1) 0.60
Anorexia 4 (1.3) 4 (4) 0 0.01
Chickenpox 1 (0.3) 0 1 (0.5) 1.00
Impetigo 1 (0.3) 0 1 (0.5) 1.00
Pruritus 1 (0.3) 0 1 (0.5) 1.00
Dehydration 1 (0.3) 0 1 (0.5) 1.00
Splenomegaly 1 (0.3) 0 1 (0.5) 1.00
Abdominal pain  †  3 (1) 1 (1) 2 (1) 1.00
Tonsilitis 1 (0.3) 1 (1) 0 0.32
Hypertension 2 (0.7) 0 2 (1) 1.00
Anemia 6 (2) 2 (2) 2 (2) 1.00
Renal stone 1 (0.3) 0 1 (0.5) 1.00
Mumps 1 (0.3) 0 1 (0.5) 1.00
Epistaxis 1 (0.3) 1 (1) 0 0.32
Upper respiratory 
infection 12 (4) 3 (3) 9 (4.5) 0.75
    *      Values are no. (%). Symptoms are given for only those 269 patients ≥ 3 years of age and 
able to answer questions about these symptoms. AE = adverse event.   
    †     Denominators were 269 for all patients, 87 for the AM group, and 182 for the DP group.   
    ‡     Cardiologic AE was any abnormality found on electrocardiographs.   
    §      Complete right bundle block. One patient had incomplete right bundle branch block 
(RBBB) on admission but complete RBBB at day 2 and incomplete RBBB on days 7, 28, and 
63. Another patient had incomplete RBBB on day 0 but complete RBBB on days 2, 7, 28, and 
63. These two patients were healthy and auscultation results of their hearts were normal.   
    ¶     Prolonged QTc was defined as a QTc interval > 450 ms.   
    #     Lung abnormalities were crepitations, rhonchi, or wheezing.   1226 MAYXAY AND OTHERS
 Table 4 
    Electrocardiographic analysis of patients in a study comparing AM and DP for treatment of   Plasmodium falciparum   malaria  in  Laos *   
    *     Values are mean (95% confidence interval) unless otherwise indicated. AM = mefloquine plus artesunate for 3 days; DP = dihydroartemisinin plus piperaquine for 3 days.   
    †     Significantly different compared with baseline (  P   ≤ 0.001).   
    §     Proportion of prolonged QTc reading by using Bazzet’s correction.   
    ¶     No. patients with QTc duration on days 2 and 7 by using Bazzet’s correction.   
Variable
AM (n = 98) DP (n = 202)
Baseline Day 2 Day 7 Baseline Day 2 Day 7
Heart rate, beats/min 115.9 (109.7–122.1) 96.1  †   (90.5–101.7) 96.9  †   (91.2– 102.7) 114.1 (109.9–118.3) 92.8  †   (88.5–97.1) 96.8  †   (92.8–100.7)
QTc Bazzet’s, ms 422.3 (418.0–426.6) 426.5 (422.2–430.8) 427.4 (422.6–432.2) 421.2 (417.5–424.8) 430.7  †   (427.4–343.0) 422.5 (419.6–425.4)
PR interval, ms 131.3 (127.1–135.5) 140.8  †   (136.4–145.2) 137.5  †   (133.3–141.7) 135.4 (132.7–138.0) 140.9  †   (137.8–144.2) 139.2  *   (135.9–142.7)
QRS interval, ms 80.0 (77.6–82.4) 83.1  †   (80.6–85.6) 80.8 (78.1–83.5) 79.8 (77.9–81.2) 81.7  †   (79.9–83.5) 79.4 (77.7–81.2)
Correlation between 
QTc and RR 
interval
r = 0.001
  P   = 0.99
r = −0.25
  P   = 0.01
r = −0.25
  P   = 0.01
r = −0.09
  P   = 0.23
r = 0.13
  P   = 0.06
r = −0.04
  P   = 0.57
QTc interval, ms  § 
< 450 89 (92) 83 (86) 81 (85) 181 (90) 167 (85) 177 (90)
450–479 8 (8) 13 (14) 12 (13) 17 (8) 22 (11) 17 (9)
480–500 0  0  2 (2) 2 (1) 7 (3.5) 2 (1)
> 500 0  0  0  1 (0.5) 1 (0.5) 0 
QTc lengthening, ms  ¶ 
< 30 – 83 (87) 76 (81) – 169 (86) 172 (88)
30–60 – 11 (12) 16 (17) – 25 (13) 20 (10)
> 60 – 1 (1) 2 (2) – 2 (1) 3 (1.5)
significantly prolonged on day 2 than at baseline in the DP 
group (  P   < 0.001) (  Table 4  ). The mean (95% CI) QTc (ms) 
prolongation on days 2 and 7 compared with those at baseline 
were 3.5 (−1.1 to 8.2) and 5.2 (−0.9 to 11.4), respectively, for 
the AM group and 9.5 (5.9–13.1) and 1.4 (−2.5 to 5.4), respec-
tively, for the DP group. The proportion of the patients with 
prolonged QTc pre-treatment and on days 2 and 7 did not dif-
fer significantly between the AM and DP groups (  P   > 0.05) 
(  Table 4  ). The numbers of patients with QTc lengthening 
(defined as > 30 ms and > 60 ms by the U.S. Food and Drug 
Administration  23,  24  ) were not significantly different between 
the two treatment groups (  P   > 0.05) (  Table 4  ). 
    DISCUSSION 
  This study confirms that the fixed-dose, co-formulated ACT 
dihydroartemisinin-piperaquine is not inferior to the more 
expensive, not co-formulated AM in the treatment of uncom-
plicated   P. falciparum   malaria in southern Laos and showed a 
63-day follow-up cure rate of almost 100% for both drugs. Our 
previous study conducted in the same area, using GMP drugs 
from China, also demonstrated that the 42-day follow up cure 
rates were 99% and 100% in AM and DP groups, respec-
tively.  11   The present study was part of a large multi-center 
trial in Asia that enrolled 1,150 patients.  12   The overall day 63 
cure rates at all sites were 97.0% for the DP group and 95.3% 
for the AM group in the modified ITT population and 98.7% 
for the DP group and 97.0% for the AM group in the per 
protocol population, which exceed the World Health Organiza-
tion acceptance threshold for day 63 PCR-corrected cure rates 
of 95%. 
 The 26 published clinical trials conducted in Asia, Africa, and 
South America that compared the efficacy of DP with other 
ACT regimens (  Table 5  ) show cure rates after treatment with 
DP, regardless of duration of follow up, of > 95% in 22 of the 
26 studies. In a meta-analysis of individual patient data from 
7 trials in Africa and Southeast Asia that included 1,814 patients 
with uncomplicated   P. falciparum   malaria who were treated 
with DP, the 63 day PCR-corrected cure rate was 97.7%.  53   
            An important limitation of this trial for public health pol-
icy in Laos is that DP was compared with AM and not with 
AL, which is the current Lao national treatment policy. 
Artesunate-mefloquine was the comparator because this 
was required for the multicentre trial. In 2005, AM was the 
intended national treatment policy but sudden and unexpected 
unavailability of AM led the Government of Laos to change 
to AL. Artesunate-mefloquine is national policy in Cambodia, 
Myanmar (Burma), and Thailand, and DP is national policy in 
Vietnam and China. There have been six comparisons of DP 
versus AL, all in children from Africa, and the 28–63-day cure 
rates were not significantly different between AL (84–96%) 
and DP (93–100%).  25–  30  
  In the multi-center study, overall   P. falciparum   gametocyte 
prevalence (days 0–70) measured as person-gametocyte-weeks 
was significantly higher after DP than AM (9.7% versus 4.8%; 
  P   = 0.006; modified ITT).  12   In addition, Zwang and others  53  
found that the proportion of patients in whom gametocytemia 
developed and the gametocyte carriage rate was higher after 
DP than after the comparator. However, in Laos, the propor-
tion of patients with gametocytemia at any time point on or 
after day 7 and the mean (95% CI) person-gametocyte-weeks 
did not significantly differ between the AM and DP groups, 
probably because of the smaller sample size. 
  Of 26 published clinical trials of either DP or DP plus 
trimethoprim (  Table 5  ) that included 6,010 patients, 8 deaths 
were reported (6 children and 2 adults). One adult death was 
probably caused by severe malaria that developed during 
treatment with DP; the other seven deaths were considered 
unlikely to be a consequence of DP. No deaths were reported 
in the larger multi-center trial of DP in Asia of 767 patients, of 
which this trial was a part.  12  
  Although piperaquine has a chemical structure similar 
to chloroquine, which can cause lethal cardiologic effects,  31  
results of our study are consistent with that of previous studies, 
which suggested that at therapeutic doses, DP does not have 
clinically significant effects on the ECG results.  32–  34  
  In Laos, AL is provided by the Global Fund at a cost of < 1.4 
U.S.$/adult treatment course and is free to patients through 1227 DIHYDROARTEMISININ-PIPERAQUINE FOR P. FALCIPARUM MALARIA
the public sector. When compared with AL, DP has potential 
benefits because it is less expensive to manufacture, may have 
better adherence, and can be used in a once a day regimen 
rather than a twice a day regimen. Although a study of the 
unsupervised effectiveness and supervised efficacy of DP and 
AM treatment in western Myanmar suggested good adher-
ence to both regimens, there have been no studies directly 
comparing DP and AL adherence.  35   Although DP has been 
successfully used as rescue therapy for multidrug-resistant 
  P. falciparum   malaria in pregnancy (PCR-adjusted cure rate at 
63 days was 92%),  36   further studies are needed to establish its 
safety in pregnancy. 
  In conclusion, DP demonstrated non-inferiority to the refer-
ence treatment of AM in Laos and in the overall three-country 
study. The high efficacy and relative safety of DP and its avail-
ability as a fixed combination and probable lower cost com-
pared with other candidate ACTs suggests that it could play 
a significant role in the first-line treatment of uncomplicated 
  P. falciparum   malaria in Laos. 
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 Table 5 
    Review of efficacy or effectiveness of DP in 26 clinical trials (1,004 adults; 2,976 children; 2,030 not identified as children or adults; total = 6,010)  *     
Reference Country Comparator
Day of 
follow-up
No. patients
Cure rate 
(%) No. deaths Adult Child
Asia
 37  China 0 28 60 96.7 Unknown
 38  China AL 28 51 100 Unknown
  39  Cambodia 0 56 30 76 95.5 1 child (8-year old boy) at day 4
 33  Cambodia 0 28 32 30 100 None  reported
  40  Cambodia A + M 64 215 97.5 None reported
  41  Vietnam A + M 56 76 97.4 None reported
40 283 98.7 None reported
  42  Vietnam AQ + P 28 84 0 94 None reported
  43  Vietnam A + AQ 42 34 15 100 None reported
  44  Thailand A + M 28 234 0 97 None reported
  34  Thailand A + M 28 134 0 98 None reported
63 353 97 1 man at day 28 from gunshot
  45  Thailand A + M 28 120 0 99 None reported
  46  Thailand A + M 63 333 99.7 1 woman at < 24 hours after admission in the clinic 
(probably from severe malaria) unlikely caused 
by DP. 1 girl (13 years of age) at day 3 (unlikely 
caused by DP).
  47  Thailand AN + PPQ, A + M, and AL 28 82 98.8 None reported
  35  Burma A + M 42 327 99 One 11-year old died aparasitemic at day 21
  11  Laos A + M 42 36 74 100 A 2-year old boy died aparasitemic at day 37
  48  Indonesia A + AQ 42 92 76 96 None reported
  49  Papua New Guinea CQ + SP, A + SP, and AL 42 482 88 None reported
  50  Vietnam AN + PPQ 28 51 100 None reported
Africa
 28  Uganda AL 63 0 351 †  98 None  reported
  29  Burkina Faso, Kenya, 
Mozambique, 
Uganda, Zambia
AL 42 0 1,039 86 1 child (3 year-old girl) died 24 hours after 
treatment with DP. The most likely cause was 
sepsis or severe malaria.
  51  Rwanda A/SP + AQ 28 0 252 95.2 None reported
 25  Uganda AL 42 0 211 93 None  reported
  30  Kenya AL 28 0 73 100 1 child (63 months of age) at day 13 unrelated to 
DP (probably caused by broncho-pneumonia)
 27  Uganda AL 42 0 215 98 None  reported
  26  Burkina Faso AQ + SP and AL 42 0 187 98 None reported
South America
  52  Peru A + M 63 168 94 98.4 None reported
    *     DP = dihydroartemisinin plus piperaquine for 3 days; AL = artemether-lumefantrine; A = artesunate; AN = artemisinin; M = mefloquine; AQ = atovaquone; P = proquanil; PPQ = piperaquine; 
CQ = chloroquine; SP = sulfadoxine-pyrimethamine.   
    †     No. treatments rather than no. patients (longitudinal study).   1228 MAYXAY AND OTHERS
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